Sawgrass Asset Management LLC Sells 680 Shares of Cencora, Inc. (NYSE:COR)

Sawgrass Asset Management LLC cut its position in shares of Cencora, Inc. (NYSE:COR) by 13.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,395 shares of the company’s stock after selling 680 shares during the quarter. Sawgrass Asset Management LLC’s holdings in Cencora were worth $987,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in COR. Sylvest Advisors LLC bought a new stake in Cencora in the fourth quarter worth $1,105,000. Insight Wealth Strategies LLC boosted its holdings in Cencora by 124.6% in the fourth quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock worth $4,549,000 after acquiring an additional 11,232 shares in the last quarter. Cerity Partners LLC boosted its holdings in Cencora by 10.1% in the third quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock worth $8,881,000 after acquiring an additional 3,610 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. boosted its holdings in Cencora by 71.1% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company’s stock worth $1,583,000 after acquiring an additional 2,928 shares in the last quarter. Finally, Portfolio Design Labs LLC bought a new stake in Cencora in the third quarter worth $1,404,000. 97.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. UBS Group upped their price target on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Wells Fargo & Company upped their price target on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a report on Wednesday, January 29th. Robert W. Baird upped their price target on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. upped their price target on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Finally, Evercore ISI upped their price target on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $277.90.

Cencora Trading Down 1.3 %

Shares of NYSE COR opened at $243.55 on Thursday. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.53 and a current ratio of 0.92. The business’s 50 day moving average price is $238.70 and its 200-day moving average price is $237.21. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $262.26. The company has a market cap of $47.07 billion, a price-to-earnings ratio of 34.64, a PEG ratio of 1.49 and a beta of 0.49.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, sell-side analysts expect that Cencora, Inc. will post 15.36 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be issued a $0.55 dividend. The ex-dividend date is Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.90%. Cencora’s dividend payout ratio is presently 31.29%.

Insider Activity

In other news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the sale, the chairman now owns 306,752 shares of the company’s stock, valued at $74,283,064.32. This trade represents a 6.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 73,187 shares of company stock worth $17,790,912. 10.80% of the stock is currently owned by company insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.